Literature DB >> 15079025

The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study.

A J C Slooter1, M Cruts, A Hofman, P J Koudstaal, D van der Kuip, M A J de Ridder, J C M Witteman, M M B Breteler, C Van Broeckhoven, C M van Duijn.   

Abstract

It is unclear how the APOE genotype contributes to the incidence of vascular diseases and dementia. In a population-based sample (n = 6,852) with complete follow-up, APOE was weakly associated with myocardial infarction and not related with stroke. In the absence of epsilon4, the incidence of dementia would be 25.8% lower; in the absence of epsilon2/epsilon3, 2.8% higher. Risk estimates of dementia, specified for age, sex, and APOE, are provided for counseling. APOE is not strongly related to vascular diseases, but contributes substantially to dementia incidence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15079025     DOI: 10.1212/01.wnl.0000118302.66674.e1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Usefulness of cognitive dysfunction in heart failure to predict cardiovascular risk at 180 days.

Authors:  Jill M Gelow; James O Mudd; Christopher V Chien; Christopher S Lee
Journal:  Am J Cardiol       Date:  2015-01-07       Impact factor: 2.778

3.  APOE-epsilon4 predisposes to cognitive dysfunction following uncomplicated carotid endarterectomy.

Authors:  E J Heyer; D A Wilson; D H Sahlein; J Mocco; S C Williams; R Sciacca; A Rampersad; R J Komotar; J Zurica; A Benvenisty; D O Quest; G Todd; R A Solomon; E S Connolly
Journal:  Neurology       Date:  2005-10-05       Impact factor: 9.910

4.  Coronary Artery Calcium and Risk of Dementia in MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Akira Fujiyoshi; David R Jacobs; Annette L Fitzpatrick; Alvaro Alonso; Daniel A Duprez; A Richey Sharrett; Teresa Seeman; Michael J Blaha; José A Luchsinger; Stephen R Rapp
Journal:  Circ Cardiovasc Imaging       Date:  2017-05       Impact factor: 7.792

Review 5.  Poststroke dementia in the elderly.

Authors:  Marie-Anne Mackowiak-Cordoliani; Stéphanie Bombois; Armelle Memin; Hilde Hénon; Florence Pasquier
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Incidence rates of dementia, Alzheimer disease, and vascular dementia in the Japanese American population in Seattle, WA: the Kame Project.

Authors:  Amy R Borenstein; Yougui Wu; James D Bowen; Wayne C McCormick; Jay Uomoto; Susan M McCurry; Gerard D Schellenberg; Eric B Larson
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

7.  Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly.

Authors:  Mary N Haan; Elizabeth R Mayeda
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-07-16

8.  Examination of candidate exonic variants for association to Alzheimer disease in the Amish.

Authors:  Laura N D'Aoust; Anna C Cummings; Renee Laux; Denise Fuzzell; Laura Caywood; Lori Reinhart-Mercer; William K Scott; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

9.  APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans.

Authors:  Lei Yu; Michael W Lutz; Robert S Wilson; Daniel K Burns; Allen D Roses; Ann M Saunders; Jingyun Yang; Chris Gaiteri; Philip L De Jager; Lisa L Barnes; David A Bennett
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

10.  Effects of Apolipoprotein E polymorphism on carotid intima-media thickness, incident myocardial infarction and incident stroke.

Authors:  Anitha Pitchika; Marcello Ricardo Paulista Markus; Sabine Schipf; Alexander Teumer; Sandra Van der Auwera; Matthias Nauck; Marcus Dörr; Stephan Felix; Hans-Jörgen Grabe; Henry Völzke; Till Ittermann
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.